anyon hear
base busi remain steadi jakafi revenu y-o-i short
consensu due inventori build approxim remov
inventori build jakafi would grown q-o-q product royalti jakavi
olumi ex-u sale respect guidanc sg
expens includ expens relat global pre-launch activ
epacadostat anticip updat estim accordingli long-term tax
rate project fulli util net oper loss tax credit
carry-forward reiter buy see favor risk/reward level
growth driven consist patient demand myelofibrosi mf
polycythemia vera pv increas persist pv approxim
patient jakafi highlight sale impact gross-
to-net price adjust medicar donut hole guidanc
bracket consensu estim manag reiter
anticip competit threat celg purchas fedratinib mf market
risk/reward skew upsid remain hope
upcom phase result epacadostat plu keytruda first-lin
melanoma highli binari catalyst note manag absolut confid
progression-fre surviv analysi take place data safeti
monitor committe like look overal surviv unclear whether
data commun public hypothet remov epacadostat
pipelin npv valuat result floor valuat around
suggest favor risk/reward investor inci current valuat
howev acknowledg investor concern around lack random control data
convict benefit keytruda monotherapi
result jakafi phase steroid-refractori acut graft-versus-host diseas
phase inhibitor cholangiocarcinoma anticip
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani focus drug
develop hematology/oncolog
inflamm multipl market product
includ inhibitor jakafi approv
myelofibrosi polycythemia vera olumi
baricitinib approv ra eu iclusig
cml baricitinib regulatori review us
emerg rich clinic stage
rate share buy see signific
valu market product jakafi ruxolitinib
mf pv see signific potenti
compani robust pipelin baricitinib
approv eu regulatori review ra
us epacadostat ido inhibitor
liquid solid tumor
po deriv probability-adjust npv analysi includ
jakafi call jakavi ex-u mf pv jakafi gvhd
epacadostat ido inhibitor baricitinib call olumi ex-u
iclusig earli pipelin also includ approx net
cash use wacc termin valu
downsid risk price object weaker-than-expect sale jakafi mf
pv unfavor efficaci and/or safeti data epacadostat clinic
trial earlier-than-expect more-than-expect competit jakafi
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
